Sylvain Peuget

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: BRITISH JOURNAL OF CANCER. 2022;127(11):2060-2071

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246.

Zhou X; Santos GS; Zhan Y; Oliveira MMS; Rezaei S; Singh M; Peuget S; Westerberg LS; Johnsen JI; Selivanova G
Article: MOLECULAR CANCER THERAPEUTICS. 2022;21(10):1524-1534

Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.

Zhan Y; Zhou X; Peuget S; Singh M; Peyser BD; Fan Z; Selivanova G
Article: ONCOGENE. 2022;41(15):2173-2186

Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization.

Aschtgen M-S; Fragkoulis K; Sanz G; Normark S; Selivanova G; Henriques-Normark B; Peuget S
Article: BREAST CANCER RESEARCH. 2020;22(1):80

Identification and targeting of selective vulnerability rendered by tamoxifen resistance.

Singh M; Zhou X; Chen X; Santos GS; Peuget S; Cheng Q; Rihani A; Arnér ESJ; Hartman J; Selivanova G
Article: CANCER RESEARCH. 2020;80(7):1538-1550

Thermal Proteome Profiling Identifies Oxidative-Dependent Inhibition of the Transcription of Major Oncogenes as a New Therapeutic Mechanism for Select Anticancer Compounds.

Peuget S; Zhu J; Sanz G; Singh M; Gaetani M; Chen X; Shi Y; Saei AA; Visnes T; Lindström MS; Rihani A; Moyano-Galceran L; Carlson JW; Hjerpe E; Joneborg U; Lehti K; Hartman J; Helleday T; Zubarev R; Selivanova G
Article: SCIENTIFIC REPORTS. 2020;10(1):1049

Pifithrin-α alters p53 post-translational modifications pattern and differentially inhibits p53 target genes.

Zhu J; Singh M; Selivanova G; Peuget S
Article: CELL DEATH & DISEASE. 2019;10(11):845

RITA requires eIF2α-dependent modulation of mRNA translation for its anti-cancer activity.

Ristau J; van Hoef V; Peuget S; Zhu J; Guan B-J; Liang S; Hatzoglou M; Topisirovic I; Selivanova G; Larsson O
Article: SCIENTIFIC REPORTS. 2019;9(1):2379

Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data.

Franco M; Jeggari A; Peuget S; Böttger F; Selivanova G; Alexeyenko A
Article: CANCER CELL. 2014;26(6):863-879

Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.

Chaluvally-Raghavan P; Zhang F; Pradeep S; Hamilton MP; Zhao X; Rupaimoole R; Moss T; Lu Y; Yu S; Pecot CV; Aure MR; Peuget S; Rodriguez-Aguayo C; Han H-D; Zhang D; Venkatanarayan A; Krohn M; Kristensen VN; Gagea M; Ram P; Liu W; Lopez-Berestein G; Lorenzi PL; Børresen-Dale A-L; Chin K; Gray J; Dusetti NJ; McGuire SE; Flores ER; Sood AK; Mills GB
Article: MOLECULAR AND CELLULAR ONCOLOGY. 2014;1(3):e964044

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53.

Bonacci T; Peuget S; Soubeyran P; Iovanna J; Dusetti NJ
Article: CELL DEATH AND DIFFERENTIATION. 2014;21(7):1107-1118

Oxidative stress-induced p53 activity is enhanced by a redox-sensitive TP53INP1 SUMOylation.

Peuget S; Bonacci T; Soubeyran P; Iovanna J; Dusetti NJ
Article: AMERICAN JOURNAL OF PATHOLOGY. 2013;182(6):1996-2004

Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreas.

Al Saati T; Clerc P; Hanoun N; Peuget S; Lulka H; Gigoux V; Capilla F; Béluchon B; Couvelard A; Selves J; Buscail L; Carrier A; Dusetti N; Dufresne M
Article: RESULTS IN IMMUNOLOGY. 2013;3:51-56

Development of an ELISA detecting Tumor Protein 53-Induced Nuclear Protein 1 in serum of prostate cancer patients.

Saadi H; Seillier M; Sandi MJ; Peuget S; Kellenberger C; Gravis G; Dusetti NJ; Iovanna JL; Rocchi P; Amri M; Carrier A
Article: CELL DEATH AND DIFFERENTIATION. 2012;19(9):1525-1535

TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death.

Seillier M; Peuget S; Gayet O; Gauthier C; N'Guessan P; Monte M; Carrier A; Iovanna JL; Dusetti NJ
Article: ONCOGENE. 2011;30(27):3049-3061

TP53INP1 decreases pancreatic cancer cell migration by regulating SPARC expression.

Seux M; Peuget S; Montero MP; Siret C; Rigot V; Clerc P; Gigoux V; Pellegrino E; Pouyet L; N'Guessan P; Garcia S; Dufresne M; Iovanna JL; Carrier A; André F; Dusetti NJ

Alla övriga publikationer

Review: NATURE REVIEWS CANCER. 2024;24(3):192-215

Translating p53-based therapies for cancer into the clinic.

Peuget S; Zhou X; Selivanova G
Editorial comment: CANCER DISCOVERY. 2023;13(5):1043-1045

MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation.

Peuget S; Selivanova G
Editorial comment: CANCERS. 2021;13(19):4850

p53-Dependent Repression: DREAM or Reality?

Peuget S; Selivanova G
Review: JOURNAL OF MOLECULAR CELL BIOLOGY. 2019;11(7):586-599

Inhibition of p53 inhibitors: progress, challenges and perspectives.

Sanz G; Singh M; Peuget S; Selivanova G
Preprint: BIORXIV. 2018

Robust and clinically relevant prediction of response to anti-cancer drugs via network integration of molecular profiles

Franco M; Jeggari A; Peuget S; Böttger F; Selivanova G; Alexeyenko A
Book chapter: ANTIOXIDANT ENZYME. 2012;p.

Antioxidant Role of p53 and of Its Target TP53INP1

Seillier M; Peuget S; Dusetti NJ; Carrier A

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI